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A B S T R A C T
Purpose: Epilepsy is well known as a disorder in poststroke patients. However, studies that have
investigated the association between epilepsy and the risk of subsequent stroke are limited. This
population-based study investigated the incidence and risk of stroke in patients with epilepsy by using
the Taiwan National Health Insurance claims data.
Methods: We identiﬁed 3812 patients newly diagnosed with epilepsy in 2000–2008 and 15,248
nonepilepsy comparisons frequency matched according to sex, age, and index year. We searched for
subsequent stroke diagnoses in both cohorts until the end of 2009. The incidence rates and hazard ratios
of stroke were estimated based on sex, age, the average deﬁned daily doses (DDDs) of antiepilepsy drugs,
and comorbidity.
Results: The stroke incidence of the epilepsy cohort was 3-fold higher than that of the comparison
cohort. The age-speciﬁc results indicated that in the epilepsy cohort and the comparison cohort, the risk
was the highest for the youngest group (20–39 years).
Conclusion: The patients with epilepsy exhibited a higher incidence of cerebral stroke than the general
population did. In addition, younger patients with epilepsy and patients who took a high doses of
antiepileptic drugs exhibited a high risk of stroke.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Previous studies have determined that patients with epilepsy
developed a wider range of medical and neurologic disorders,
compared with the general population.1,2 The comorbidities
include somatic disorders, such as cardiac, gastrointestinal, and
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have reported that patients with epilepsy exhibited a higher
mortality rate than did the general population. Stroke was one of
the major fatal causes.8–11
Using certain antiepileptic drugs (AEDs) has been associated
with an increased risk of atherosclerosis,12 suggesting that these
drugs could be responsible for increased cardiovascular risk in
patients with epilepsy.13 According to a review of relevant
literature, we concluded that patients with epilepsy are at a
higher risk of stroke than the general population is.14,15 However,
previous studies might have been limited by a cross-sectional
design, small sample sizes, or confounding effects.
Epilepsy is well known as a disorder in poststroke patients.16–18
Studies that have investigated the association of epilepsy with the
risk of subsequent stroke are limited.3,5 This study used the UK
General Practice Research Database, which indicated a relativeserved.
Table 1
Characteristic of the study population.
Variable Comparison cohort Epilepsy cohort P-Value
N = 15,248 (%) N = 3812 (%)
Age, mean (SD)a 50.0 (18.2) 50.1 (18.3) 0.9082
20–39 5116 (33.6) 1279 (33.6) >0.99
40–59 5436 (35.7) 1359 (35.7)
360 4696 (30.8) 1174 (30.8)
Sex >0.99
Female 6352 (41.7) 1588 (41.7)
Male 8896 (58.3) 2224 (58.3)
Comorbidity
Hypertension 5540 (36.3) 1385 (36.3) >0.99
AF 145 (1.0) 78 (2.0) <0.0001
CAD 2084 (13.7) 521 (13.7) >0.99
Diabetes 2284 (15.0) 571 (15.0) >0.99
Hyperlipidemia 2916 (19.1) 729 (19.1) >0.99
a t-Test.
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late-life.5 The risk remains unclear regarding young patients with
epilepsy.
We used the National Health Insurance (NHI) Research
Database to evaluate the risk of stroke among adult patients with
epilepsy in a 10-year follow-up period. This population-based
retrospective cohort study addressed the epilepsy-cerebral stroke
link, considering the associations with sex, age, the average deﬁned
daily doses (DDDs) of antiepilepsy drugs, and comorbidities.
2. Methods
2.1. Data source
Taiwan ofﬁcially commenced the NHI program in March 1995,
providing universal health insurance to 99% of the population and
92% of the medical institutions in Taiwan were included in the
system.19–21
This study used the Longitudinal Health Insurance Database,
which includes historical claims data from 1996 to 2009 for
1 million people randomly sampled by the National Health
Research Institute (NHRI) from the entire insured population
registered in 2000. Disease diagnoses were coded using the
International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM) for the diagnosis of disease. The
outpatient claims data consisted of 3 diagnoses, and the inpatient
claims data consisted of 5 diagnoses, accompanied by detailed
pharmaceutical prescriptions and treatment procedures. The NHRI
scrambled patient identiﬁcations and used surrogate numbers
to secure patient privacy. The present study was approved by the
ethics committee at China Medical University and Hospital.
2.2. Study population
To increase the validity of the diagnoses, we selected patients
newly diagnosed with epilepsy in 2000–2008 (ICD-9-CM, code
345), who were prescribed antiepileptic drugs, as the epilepsy
cohort.18 The index date of the epilepsy cohort was set as the
epilepsy diagnosis date. Patients in the comparison cohort were
randomly selected from individuals who were free from epilepsy in
1996–2008 and frequency matched according to sex, age (per 5
years), and all comorbidities, except for atrial ﬁbrillation (AF)
(AF was not included in the frequency criteria because of low AF
prevalence in individuals without epilepsy; however, the propor-
tion of AF in the epilepsy cohort was 2.0%, and that in the
comparison cohort was 1.0%), yielding a 4-fold sample size.
The index date for the comparison cohort was randomly assigned
the same month and day as the index year of the matched case.
The follow-up time was terminated on the date of stroke event
diagnosis, withdrawal from the insurance program, or on
December 31, 2009. The event of interest in the study was a
subsequent new stroke event (ICD-9-CM 430–438), which was
determined by brain imaging, that was identiﬁed using the
inpatient ﬁle. We also distinguished the stroke events as either
ischemic strokes (ICD-9-CM 433–438) or hemorrhagic strokes
(ICD-9-CM 430–432), excluding stroke patients aged less than
20 years.
We also calculated the average DDDs of AEDs in the epilepsy
cohort as the total sum of AEDs used during the observation time
divided by the total follow-up duration (DDD/year). The AEDs
were phenytoin (ATC code: N03AB02), carbamazepine (ATC code:
N03AF01), gabapentin (ATC code: N03AX12), levetiracetam (ATC
code: N03AX14), oxcarbazepine (ATC code: N03AF02), tiagabine
(ATC code: N03AG06), topiramate (ATC code: N03AX11), vigaba-
trin (ATC code: N03AG04), phenobarbital (ATC code: N03AA02),
and valproate (ATC code: N03AG01). The epilepsy cohort wasrecategorized into 3 subcohorts according to the tertile cutpoint
of the average DDDs.
Information on potential confounders, such as demographic
factors or the comorbidity of stroke, were also collected in this
study. The comorbidities used in this study were hypertension
(ICD-9-CM 401–405) and hyperlipidemia (ICD-9-CM 272), both
of which were diagnosed at least 3 times; diabetes mellitus
(DM)(ICD-9-CM 250), diagnosed at least 2 times; coronary artery
disease (CAD)(ICD-9-CM 410–413, 414.0, 414.8, and 414.9); and
AF (ICD-9-CM 427.3), diagnosed once.
2.3. Statistical analysis
We used Chi-square tests to examine the categorical variables
and t tests to examine the continuous variables to compare the
characteristics between the epilepsy and comparison cohorts. The
incidence of stroke in the 2 groups was determined. Compared
with the comparison cohort, the hazard ratio (HR) and 95%
conﬁdence interval (CI) of stroke for the epilepsy cohort were
estimated using the Cox proportional hazards regression model
after adjusting for AF. The Kaplan–Meier method was used to
evaluate the stroke-free curves of stroke for the epilepsy and
comparison cohorts, and the variations in the curves were
examined using logrank tests.
Statistical analysis and data management were performed
using the Statistical Analysis System (SAS) 9.3 (SAS Institute Inc.,
Cary, NC, USA), and the survival curve was determined using
R 2.13.0 (The R Foundation for Statistical Computing, Vienna,
Austria). A P value less than 0.05 was considered signiﬁcant.
3. Results
This study used 15,248 comparison individuals and 3812
patients with epilepsy, yielding a mean age of 50 years, and 41.7%
of the participants were women (Table 1). Except for AF, the
distribution of all the comorbidities between the epilepsy and
comparison cohorts was similar (P > .99).
The results of using the Kaplan–Meier model shown in Fig. 1
indicated that the cumulative incidence of stroke for the epilepsy
cohort was signiﬁcantly higher than that for the comparison cohort
(logrank test < 0.0001). The incidence of stroke was approximately
3-fold higher in the epilepsy cohort than in the comparison cohort
(24.08 vs. 7.96 per 1000 person-year), yielding an HR of 2.92 (95%
CI = 2.58–3.30) after adjusting for AF (Table 2). The incidence of
ischemic stroke was nearly 3-fold higher than that of hemorrhagic
stroke for both cohorts. Compared with the comparison cohort,
the epilepsy cohort exhibited HRs of 2.85 (95% CI = 2.49–3.26) for
ischemic stroke and 3.30 (95% CI = 2.46–4.43) for hemorrhagic
Fig. 1. The Kaplan–Meier model used to measure the cumulative incidence curve for
stroke in the study cohort.
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who had the lowest dose of AED exposure exhibited a 1.30-fold
increased risk of developing stroke (HR = 1.30, 95% CI = 1.03–1.64),
and the epilepsy patient who had the highest dose of AED exposure
exhibited the greatest increased risk of stroke (HR = 5.84, 95%
CI = 5.02–6.80). The results also indicated that the risk of overall
stroke, ischemic stroke, and hemorrhagic stroke occurrences
increased as AED exposure increased (P for trend < .0001).
Table 3 shows the stratiﬁcation analysis for the risk of
subsequent stroke and the demographic factor and comorbidity
statuses of the study cohorts. The stroke risk was higher for men
than for women and increased as age increased. However, the
age-speciﬁc HR for the epilepsy cohort, compared with that of
the comparison cohort, was highest in the young patients aged 20–
39 years (HR = 8.88, 95% CI = 5.71–13.82). Regarding the patients
not presenting with comorbidities, the epilepsy cohort exhibited
an adjusted HR of 5.88 (95% CI = 4.58–7.56) for stroke, compared
with the comparison cohort. The comorbidity-speciﬁc adjusted HR
for the epilepsy cohort ranged between 1.93 and 2.66, compared
with the comparison cohort.
4. Discussion
After adjusting for potential confounding factors, including
demographic factors and the comorbidity of stroke, the results of
the present study indicated that the incidence of ischemic strokeTable 2
The incidence and hazard ratio for stroke.
All stroke Ischemic 
Event Rate aHR Event 
Comparison 653 7.96 Ref 547 
Epilepsy 427 24.08 2.92(2.58–3.30) 349 
Anti-epilepsy drug useda
<5 DDD 78 10.44 1.30(1.03–1.64) 61 
5–69 DDD 121 21.31 2.58(2.13–3.14) 102 
370 DDD 228 49.77 5.84(5.02–6.80) 186 
P for trend <0.0001 
Model adjusted for AF.
aHR: adjusted hazard ratio; rate: incidence rate, per 1000 person-year.
a Average DDD, per year.for the patients with epilepsy was signiﬁcantly higher than that for
the patients in the comparison cohort. The men were at a higher
risk of ischemic stroke than the women were in this study. Cleary
et al. determined that patients who presented with seizures
after 60 years of age exhibited a substantial risk of stroke.5 Another
study determined that epilepsy may increase the risk of
cardiovascular disease and stroke.22 We also observed a sharp
increase in the incidence of stroke as age increased. The incidence
was 6.3-fold higher for the patients aged 60 years than for those
aged 20–39 years in the epilepsy cohort. No previous comprehen-
sive studies have compared the age-speciﬁc incidence of stroke in
patients with epilepsy. Based on our research, this is the ﬁrst study
to document such ﬁndings by examining data that were based on a
generalized population-based cohort.
Cerebral stroke is a heterogeneous disease that comprises
several subtypes consisting of different etiologies.23 Traditional
cardiovascular risk assessments for each sex include standard lipid
measurements (e.g., total cholesterol, low-density lipoprotein
cholesterol, and high-density lipoprotein cholesterol) and assess-
ments of nonlipid risk factors (e.g., hypertension or diabetes
mellitus). These conditions interact to promote atherosclerosis
formation, which is the artery-clogging process that causes heart
attacks and strokes.24,25 Speciﬁc diseases, such as carotid stenosis,
AF, and lifestyle-related factors (e.g., smoking, absence of regular
exercise, and being overweight) are well-known stroke risk
factors.26
Previous studies have determined that statin could potentially
prevent epilepsy.27,28 No increase in vascular risk factors was
observed in patients with epilepsy29; therefore, we attempted to
control the comorbidities between the epilepsy and comparison
cohorts in this study. In the data obtained in the present study, the
comorbidity-speciﬁc HR of stroke risk suggested that the epilepsy
cohort and control group presenting with hypertension, diabetes,
CAD, and hyperlipidemia exhibited a signiﬁcantly high risk of
stroke. Several studies have reported that the plasma concentra-
tions of total cholesterol, low-density lipoprotein cholesterol, and
its components increased in patients who were prescribed long-
term carbamazepine (CBZ),30,31 phenobarbital, or VPA therapy.32,33
Dyslipidemia causes atherosclerosis in arterial vessels.34 Increased
body weight, which is a frequently encountered side effect
associated with long-term VPA use,35,36 plays a modulatory role
in promoting these risks of vascular injury.37,38 Prospective studies
have established that increased carotid artery intimamedia
thickness (CIMT) is involved in subsequent hypertension and
dyslipidemia in adults, and that increased CIMT typically occurs in
association with an increased incidence of acute cardiovascular
and cerebrovascular events.39 High CIMT values, increased plaque
scores, the number of plaques, and the degree of carotid stenosis
have been correlated with cerebrovascular disorder.40 This study
determined that the relationship between the risk of stroke and
AEDs was dose-dependent.Hemorrhagic
Rate aHR Event Rate aHR
6.67 Ref 106 1.29 Ref
19.68 2.85(2.49–3.26) 78 4.40 3.30(2.46–4.43)
8.16 1.21(0.93–1.58) 17 2.27 1.75(1.05–2.92)
17.96 2.60(2.10–3.21) 19 3.35 2.51(1.54–4.10)
40.60 5.68(4.81–6.72) 42 9.17 6.69(4.67–9.58)
<0.0001 <0.0001
Table 3
Cox proportional hazards regression estimated hazard ratio of stroke for study cohorts with/without comorbidity and demographic factors.
Variables Comparison cohort Epilepsy cohort aHR (95% CI)
Event PYs Rate Event PYs Rate
Sex
Female 254 35,349 7.19 138 7925 17.41 2.35(1.91–2.89)
Male 399 46,680 8.55 289 9808 29.46 3.32(2.85–3.87)
Age group
20–39 29 29,725 0.98 61 7002 8.71 8.88(5.71–13.82)
40–59 124 30,341 4.09 132 6476 20.38 4.89(3.83–6.26)
360 500 21,963 22.77 234 4256 54.99 2.32(1.99–2.71)
Without any comorbidity 107 47,217 2.27 142 10,521 13.50 5.88(4.58–7.56)
Hypertension
No 154 54,958 2.80 180 12,172 14.79 5.17(4.17–6.41)
Yes 499 27,071 18.43 247 5562 44.41 2.33(2.00–2.71)
AF
No 625 81,527 7.67 406 17,537 23.15 2.99(2.64–3.39)
Yes 28 501 55.86 21 197 106.48 1.93(1.09–3.42)
CAD
No 457 72,651 6.29 339 15,745 21.53 3.32(2.88–3.82)
Yes 196 9377 20.9 88 1989 44.25 2.04(1.59–2.63)
Diabetes
No 453 71,276 6.36 335 15,627 21.44 3.26(2.83–3.76)
Yes 200 10,753 18.6 92 2107 43.66 2.27(1.77–2.91)
Hyperlipidemia
No 462 67,571 6.84 317 14,687 21.58 3.05(2.64–3.52)
Yes 191 14,457 13.21 110 3047 36.10 2.66(2.10–3.36)
Model adjusted for AF.
aHR: adjusted hazard ratio; rate: incidence rate, per 1000 person-year.
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the patients in both cohorts who did not present with any
comorbidities, the patients in the epilepsy cohort exhibited a
3-fold increased stroke risk, compared with the patients in the
comparison cohort. Regarding age, the cumulative data indicated
that the young patients (20–39 years) in the epilepsy cohort
exhibited a signiﬁcantly increased stroke risk, compared with
the patients in the comparison cohort who were in the same age
range. This is a striking ﬁnding. The possible reason is the early
onset of epilepsy and treatment resistance. We hypothesized that
the harmful effects of recurrent epilepsy and vascular risk factors
contribute to the overproduction of reactive oxygen species
and the oxidation of low-density lipoproteins into atherogenic
particles, which play a pivotal role in the pathogenesis of
atherosclerosis.41,42 In addition, Hamed et al. provided evidence
suggesting that CIMT may increase and various vascular risk
factors may worsen in patients with chronic epilepsy and/or are
provided treatment with antiepileptic medications.43 In addition,
long-term AED therapy may cause low-grade systemic inﬂamma-
tion and increased oxidative stress, which is manifested by a
substantially increased CIMT7,44 and high concentrations of high-
sensitivity C-reactive protein, which are recognized as activators
of the extrinsic pathway of the coagulation system.40,45 A positive
relationship has been observed between the duration of CBZ, PHT,
or VPA monotherapy and the acceleration of atherosclerosis in the
CIMT of patients with epilepsy, albeit by using different underlying
mechanisms.46 Young epilepsy patients might have been suffering
from seizure attacks since childhood and also might have
undergone long-term AED therapy, which contribute to the risk
of stroke.
This population-based study used a large random sample of
insured patients and provided a source for exploring the epidemio-
logic characteristics of cerebral stroke in patients with epilepsy.
Nevertheless, the present study presented several limitations. First,
the diagnosis of stroke might be overestimated among the epilepsy
cohort because mimic stroke may have occurred among the patients
with epilepsy,47,48 and no brain images were available to illustrate
the unequivocal evidence of a stroke in the database. The evaluation
process for identifying seizures and strokes might include brainimages taken by physicians to evaluate the possible etiology.
Although image data were unavailable in the claims data that we
obtained, we attempted to evaluate the incidence of stroke by
referring to the inpatient database, which used a more careful survey
for evaluating the diagnoses to prevent possible overestimation.
Second, we could not estimate the precise temporal relationships
between epilepsy and subsequent stroke occurrence because the
index date for the diagnosis of epilepsy might not have been the
onset date of the disease. This is because the diagnosis of epilepsy
was based on the date registered in the claims data after the patients
visited a physician, and because of a possible delay in the diagnosis of
epilepsy from the time of initial symptoms.27 Thus, the onset of
epilepsy might not be based on the date of diagnosis. We attempted
to estimate the incidence of stroke after the diagnosis of epilepsy.
Finally, the information on several cardiovascular risk factors,
including smoking, body mass index, the actuarial concentrations
of lipid proﬁles, blood glucose levels, blood pressure, the CIMT,
education level, and occupation were also unavailable in the
database. Furthermore, the DDD provides information on only the
prescriptions received by patients; medication adherence and effect
information was not available.
5. Conclusion
The patients with epilepsy exhibited an increased risk of cerebral
stroke even after controlling the comorbidities of stroke risk factors,
compared with the patients in the general population. This ﬁnding
indicates the key epidemiological concerns and risk factors that are
involved in the development of stroke in patients with epilepsy. This
ﬁnding may have implications for the development of prevention
strategies that can be employed when treating patients with
epilepsy, particularly for high-risk individuals.
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